(firstQuint)Memantine for Neuroprotection and Cognitive Enhancement Following Traumatic Brain Injury.

 This is a pilot/feasibility study of memantine in severe traumatic brain injury (TBI) persons, employing a randomized, double-blind, placebo-controlled, design.

 Outcome evaluations will occur after 24 weeks of treatment (on medication) and 4 weeks after treatment discontinuation.

.

 Memantine for Neuroprotection and Cognitive Enhancement Following Traumatic Brain Injury@highlight

The purpose of this study is to determine if memantine can improve cognitive and neuropsychiatric outcomes after severe traumatic brain injury.

